Annual General Meeting of Shareholders
Summary of the resolutions and voting at DSM's Annual General Meeting of Shareholders 2020.
Share types, listings & ownership
Share center
Ordinary shares Koninklijke DSM N.V.
Royal DSM N.V. is a company limited by shares listed on the Euronext Stock Exchange in Amsterdam, the Netherlands.
In addition to this official listing of ordinary shares of Koninklijke DSM N.V. (Royal DSM), options on ordinary DSM shares are traded on the European Option Exchange in Amsterdam, the Netherlands ("Euronext.liffe").
American Depositary Receipts (ADR)
In the USA, a sponsored unlisted American Depositary Receipts (ADR) programme is offered by Deutsche Bank Trust Co. Americas (Cusip 780249108), where four ADR's represent the value of one ordinary DSM share.
OTCQX International Premier
As of 6 August 2013 DSM began trading on OTCQX International Premier, a segment of the OTCQX marketplace reserved for world-leading companies that are listed on a qualified international exchange, undergo management reviews and provide their home country disclosure to U.S. investors. Koninklijke DSM N.V.’s American Depositary Receipt (ADR) is listed on OTCQX International Premier under the ticker RDSMY.
Share structure
As set out in its Articles of Association, Royal DSM has two types of shares; the ordinary shares listed on the Euronext Stock Exchange and two classes of Cumulative Preference shares, series A (Cumprefs A) and B (Cumprefs B). At this time Cumulative Preference shares series B are not issued.
- ORDINARY SHARES
- CUMPREFS A
- CUMPREFS B
- issued as at 31 December 2019: 181,425,000 shares.
- outstanding as at 31 December 2019: 172,448,755 shares.
- total outstanding as at 31 December 2019: 216,488,755 shares (Ordinary & Cumprefs).
- nominal value of €1.50 per share.
- no certificates on these shares are issued, the voting rights are not limited.
- listed on the stock market at NYSE Euronext stock exchange in Amsterdam.
As at 31 December 2019 44.04 million cumulative preference shares A (Cumprefs A) are in issue and placed with three Dutch institutional investors. Cumprefs A's are not listed on any stock market.
The Cumprefs A have the same voting rights as ordinary shares, as their nominal value of €1.50 per share is equal to the nominal value of the ordinary shares. Transfer of the Cumprefs A requires the approval of the Managing Board, unless the shareholder is obliged to transfer his shares to a previous shareholder by virtue of the law.
As the basis for the computation of the dividend on the Preference Shares A amounts to €5.2942 per share, the total dividend for 2019 equals to €0.17259 per share, which is identical to the total dividend paid on the Cumulative Preference Shares A over 2016, 2017, and 2018, respectively. While the proposed dividend for the ordinary shareholders will increase by about 4% versus 2018, the Managing Board, in consultation with the Supervisory Board, felt it appropriate to keep the dividend on the Cumulative Preference Shares A equal to that paid over 2018.
- are not issued nor outstanding at this time.
- by virtue of DSM's Articles of Association, 375,000,000 cumulative preference shares B can be issued.
- the DSM Preference Shares Foundation has the right to acquire such preference shares (call option) to a maximum corresponding to 100% of the capital issued in any form other than preference shares B, less one.
- the DSM Preference Shares Foundation is independent in accordance with the requirement laid down in Appendix X to the Listing and Issuing Rules of Euronext.
Shareholder base
Under the Dutch Financial Markets Supervision Act, shareholdings of 3% or more in any Dutch company must be disclosed to the Dutch Authority for the Financial Markets (AFM).
According to the register kept by the AFM the following shareholders disclosed that they have a direct or indirect (potential) interest between 3% and 10% in DSM’s total share capital on 31 December 2019:
- ASR Nederland N.V.
- BlackRock Inc.
- Capital Research and Management Company, Capital Group International Inc. and EuroPacific Growth Fund
- NN Group N.V.
- Rabo Participaties B.V.
Development of the number of ordinary shares in 2019
| 2019 | 2018 | |||
|---|---|---|---|---|
| Issued | Repurchased | Outstanding | Outstanding | |
| Balance at 1 January | 181,425,000 | 5,774,425 | 175,650,575 | 174,643,475 |
| Changes: | ||||
| Reissue of shares in connection with share-based payment plans | - | (3,395,405) | 3,395,405 | 2,090,107 |
| Repurchase of shares | - | 7,962,936 | (7,962,936) | (2,700,000) |
| Dividend in the form of ordinary shares | - | (1,365,711) | 1,365,711 | 1,616,993 |
| Balance at 31 December | 181,425,000 | 8,976,245 | 172,448,755 | 175,650,575 |
Share price on Euronext Amsterdam (€ per ordinary share) in 2019
| 2019 | 2018 | |
|---|---|---|
| Highest closing price | 117.90 | 92.98 |
| Lowest closing price | 69.54 | 69.98 |
| At 31 December 2018 | 116.10 | 71.44 |
| Market capitalization at 31 December 2019* | 21,063 | 12,691 |
* source Bloomberg
Geographical spread of ordinary shares 2013 - 2019
| in % (excluding cumprefs A) | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|
| Netherlands | 12 | 14 | 15 | 16 | 17 | 20 | 21 |
| North America | 39 | 38 | 37 | 39 | 34 | 32 | 26 |
| United Kingdom | 17 | 16 | 18 | 17 | 14 | 12 | 18 |
| France | 11 | 11 | 9 | 7 | 7 | 8 | 9 |
| Germany | 4 | 5 | 5 | 4 | 5 | 5 | 7 |
| Switzerland | 4 | 4 | 4 | 5 | 6 | 7 | 5 |
| Asia Pacific | 4 | 5 | 4 | 4 | 5 | 4 | 5 |
| Other | 9 | 7 | 8 | 8 | 12 | 12 | 9 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Our Investor Relations team are based in Heerlen, the Netherlands. The team provides key facts and figures, as well as shareholder information, to current and potential shareholders of DSM and to analysts. To that effect Investor Relations plans, prepares and organizes the written and oral communications with (potential) shareholders and financial analysts, deals with the stock exchange authorities and maintains the necessary databases, websites and brochures.
Dave Huizing
Vice President
Investor Relations
+31 45 578 2864
Sandra Segers
PA to Dave Huizing
Investor Relations
+31 45 578 2864
Anna Morello
Manager
Investor Relations
+31 45 578 2282
Marc Silvertand
Manager
Investor Relations
+31 45 578 2348
Daniel Uribe
Analyst
Investor Relations
+31 45 578 2864
Petra Volk
Support Officer
Investor Relations
+31 45 578 2511
Read more
-
-
Financial results & presentations
Instant overview of the financial results, presentations, updates & AGMs and all DSM's financial and regulatory press releases from the last decade.
-
Factbooks
An introduction for investors and analysts to DSM, our Nutrition, Materials and Innovation Center clusters and our businesses.